---
title: "Terex | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.243 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294736265.md"
datetime: "2026-08-03T20:40:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294736265.md)
  - [en](https://longbridge.com/en/news/294736265.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294736265.md)
generator: "portal-rs"
---

# Terex | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.243 B

Revenue: As of FY2026 Q2, the actual value is USD 2.243 B, beating the estimate of USD 2.141 B.

EPS: As of FY2026 Q2, the actual value is USD 1.37, beating the estimate of USD 1.2377.

#### Consolidated Financial Performance (Q2 2026)

Terex Corporation reported consolidated sales of $2.24 billion, an increase of $751 million or 51% as reported, and an 8.5% increase on a proforma basis compared to the prior year. Adjusted EBITDA reached $269 million, up $26 million or 10.7% year-over-year on a pro-forma basis, with an adjusted EBITDA margin of 12.0%. The company generated $128 million in operating cash flow and $101 million in free cash flow. Net working capital improved to 15.2% of sales, down from 22.8% a year ago. Net debt stood at $2.28 billion, including $407 million of cash on hand, leading to a net leverage of 2.3X net debt to 12-month adjusted EBITDA. Terex Corporation returned $20 million to shareholders through dividends during the quarter. Consolidated bookings increased 25% year-over-year on a proforma basis to $2 billion, and the backlog was $6.9 billion. 

#### Segment Performance (Q2 2026)

-   **Environmental Solutions (ES):** Sales increased 5.9% to $456 million, while adjusted EBITDA margin was 17.5%, down 250 basis points year over year. Bookings grew 18% to $417 million.
-   **Materials Processing (MP):** Sales increased 11.1% to $464 million, and adjusted EBITDA margin expanded by 440 basis points to 18.8%. Bookings increased 18% on a proforma basis to $469 million, and backlog grew 63% to $599 million.
-   **Specialty Vehicles (SV):** Sales rose 6.2% to $650 million, with adjusted EBITDA margin improving 210 basis points to 14.5%. Bookings were up 9% to $588 million.
-   **Aerials:** Sales increased 10.9% year-over-year to $673 million, but adjusted EBITDA margin was 5.7%, down 340 basis points from last year. Bookings saw a significant 71% growth to $530 million, and backlog increased 28% to $914 million.

#### Operational Metrics

U.S. non-residential construction starts rose 18% to $368 billion year to date, with mega project starts totaling approximately $80 billion through May. The REV Group integration is progressing well, and the segment delivered record earnings performance. Terex Utilities introduced the TRX product line, featuring four models that eliminate the need for a Commercial Driver’s License. The company’s price/cost position improved in the second quarter and is expected to be neutral for the full year. A strategic review of the Aerials segment is underway, with progress being made and interest from multiple parties. 

#### Outlook / Guidance (2026 Full Year)

Terex Corporation raised its full-year 2026 guidance, expecting proforma sales to grow approximately 7.4% at the mid-point, reaching a range of $7.9 billion to $8.2 billion. Proforma EBITDA is projected to grow by approximately $124 million or 14.5% year over year, ranging between $960 million and $1.0 billion, with a 12.2% EBITDA margin at the midpoint. The company anticipates delivering $300 million to $350 million in free cash flow for 2026.

### Related Stocks

- [TEX.US](https://longbridge.com/en/quote/TEX.US.md)

## Related News & Research

- [De Lisle Partners LLP Purchases Shares of 20,000 Terex Corporation $TEX](https://longbridge.com/en/news/296695717.md)
- [Research Analysts Set Expectations for Terex Q3 Earnings](https://longbridge.com/en/news/295932778.md)
- [Medtronic declares Q3 2026 dividend of R$ 0.34 per unit, payable Oct. 22](https://longbridge.com/en/news/296645069.md)
- [Lipocine 8-K/A adds Michael Grissinger to compensation committee](https://longbridge.com/en/news/296650509.md)
- [Shuttle Pharmaceuticals amends 8-K, says UDC merger not significant and financials not required](https://longbridge.com/en/news/296146163.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**